

# Alexander J Thompson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2337926/publications.pdf>

Version: 2024-02-01

59  
papers

5,789  
citations

361045  
20  
h-index

168136  
53  
g-index

60  
all docs

60  
docs citations

60  
times ranked

6188  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. <i>Nature</i> , 2009, 461, 399-401.	13.7	3,394
2	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 139, 120-129.e18.	0.6	633
3	IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 1888-1896.	3.6	332
4	Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALY&plus). <i>Hepatology</i> , 2016, 63, 1430-1441.	3.6	232
5	Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. <i>Gut</i> , 2017, 66, 1507-1515.	6.1	119
6	Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. <i>International Journal of Drug Policy</i> , 2017, 47, 107-116.	1.6	114
7	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	3.7	82
8	Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. <i>Journal of Hepatology</i> , 2019, 70, 839-846.	1.8	80
9	Viral Hepatitis B: Clinical and Epidemiological Characteristics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a024935-a024935.	2.9	74
10	Aiming for cure in HBV and HDV infection. <i>Journal of Hepatology</i> , 2016, 65, 835-848.	1.8	66
11	Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 890-899.	3.7	64
12	Chronic hepatitis C burden and care cascade in Australia in the era of interferon&dashbased treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 229-236.	1.4	61
13	A global investment framework for the elimination of hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 535-549.	1.8	51
14	<i><sc>IL</sc>28<sc>B</sc></i> genotype is not useful for predicting treatment outcome in <sc>A</sc>sian chronic hepatitis <sc>B</sc> patients treated with pegylated interferon&dash. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 861-866.	1.4	41
15	Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. <i>Hepatology, Medicine and Policy</i> , 2018, 3, 8.	1.7	39
16	Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. <i>International Journal of Drug Policy</i> , 2019, 72, 91-98.	1.6	39
17	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	1.8	30
18	The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. <i>Clinical and Translational Immunology</i> , 2016, 5, e115.	1.7	27

#	ARTICLE	IF	CITATIONS
19	<scp>ALT</scp> flares during nucleotide analogue therapy are associated with <scp>HB</scp>sAg loss in genotype A <scp>HB</scp>eAgâ€positive chronic hepatitis B. <i>Liver International</i> , 2018, 38, 1760-1769.	1.9	26
20	A model of the economic benefits of global hepatitis C elimination: an investment case. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 940-947.	3.7	26
21	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021, 73, e3288-e3295.	2.9	21
22	Higher Anti-tumor Necrosis Factor-Î± Levels Correlate With Improved Radiologic Outcomes in Crohnâ€™s Perianal Fistulas. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1306-1314.	2.4	19
23	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. <i>BMC Medicine</i> , 2019, 17, 175.	2.3	17
24	A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. <i>International Journal of Drug Policy</i> , 2020, 76, 102633.	1.6	17
25	Genetic Factors and Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2012, 142, 1335-1339.	0.6	16
26	Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review. <i>Seminars in Liver Disease</i> , 2019, 39, 341-353.	1.8	16
27	â€Teach-backâ€™ is a simple communication tool that improves disease knowledge in people with chronic hepatitis B â€ a pilot randomized controlled study. <i>BMC Public Health</i> , 2019, 19, 1355.	1.2	15
28	Long-Term Outcome of Multidisciplinary Versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2102-2111.e9.	2.4	14
29	Toll-like Receptor Expression and Signaling in Peripheral Blood Mononuclear Cells Correlate With Clinical Outcomes in Acute Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 739-747.	1.9	10
30	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 673-679.	1.4	10
31	Systematic review: efficacy of escalated maintenance anti-â€tumor necrosis factor therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 249-266.	1.9	9
32	A randomized, controlled study of peginterferon lambda-1a/ribavirinÂ±Âdaclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
33	Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age. <i>Journal of Hepatology</i> , 2020, 73, 1282-1284.	1.8	8
34	Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2020, 158, 2028-2032.	0.6	8
35	A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison. <i>International Journal of Drug Policy</i> , 2021, 94, 103203.	1.6	8
36	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018, 13, e0199198.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. PLoS ONE, 2020, 15, e0242101.	1.1	6
38	Retreatment with elbasvir, grazoprevir, sofosbuvir±Aribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse. Liver International, 2019, 39, 2285-2290.	1.9	5
39	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 487-492.	1.0	5
40	Direct-acting antiviral treatment for HCV. Lancet Infectious Diseases, The, 2016, 16, 1325-1326.	4.6	4
41	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 493-509.	1.0	4
42	Secreted and intracellular cytokines are complementary measures for human monocytes treated with Toll-like receptor agonists. Journal of Immunological Methods, 2019, 464, 131-137.	0.6	4
43	Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients. Journal of Viral Hepatitis, 2019, 26, 271-277.	1.0	4
44	Blood donation amongst people who inject drugs in Australia: research supporting policy change. Vox Sanguinis, 2020, 115, 162-170.	0.7	4
45	Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. The Lancet Regional Health - Western Pacific, 2022, 18, 100316.	1.3	4
46	Clinical application and diagnostic accuracy of artificial intelligence in colonoscopy for inflammatory bowel disease: systematic review. Endoscopy International Open, 2022, 10, E1004-E1013.	0.9	4
47	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 511-519.	1.0	2
48	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 521-534.	1.0	2
49	Effective prison-based treatment and linkage to care after release. Lancet Infectious Diseases, The, 2019, 19, 1171.	4.6	2
50	Defining Optimal Care for Functional Gut Disorders - Multi-Disciplinary Versus Standard Care: A Randomized Controlled Trial Protocol. Contemporary Clinical Trials, 2019, 84, 105828.	0.8	2
51	Quality of upper GI endoscopy: a prospective cohort study on impact of endoscopist education. Gastrointestinal Endoscopy, 2022, 96, 467-475.e1.	0.5	2
52	Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind. Gastroenterology, 2017, 152, 1282-1284.	0.6	1
53	Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 5-15.	1.4	1
54	Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia. BMC Public Health, 2022, 22, 536.	1.2	1

#	ARTICLE	IF	CITATIONS
55	99Increasing prevalence of primary biliary cholangitis in Victoria, Australia. International Journal of Epidemiology, 2021, 50, .	0.9	0
56	Title is missing!., 2020, 15, e0242101.		0
57	Title is missing!., 2020, 15, e0242101.		0
58	Title is missing!., 2020, 15, e0242101.		0
59	Title is missing!., 2020, 15, e0242101.		0